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Vascular endothelial growth factor (VEGF) was initially characterized by its activity on the
vascular system. However, there is growing evidence indicating that VEGF also acts as
a neuroprotective factor, and that its administration to neurons suffering from trauma or
disease is able to rescue them from cell death. We questioned whether VEGF could also
maintain damaged neurons in a neurotransmissive mode by evaluating the synthesis of
their neurotransmitter, and whether its action would be direct or through its well-known
angiogenic activity. Adult rat extraocular motoneurons were chosen as the experimental
model. Lesion was performed by monocular enucleation and immediately a gelatine
sponge soaked in VEGF was implanted intraorbitally. After 7 days, abducens, trochlear,
and oculomotor nuclei were examined by immunohistochemistry against choline
acetyltransferase (ChAT), the biosynthetic enzyme of the motoneuronal neurotransmitter
acetylcholine. Lesioned motoneurons exhibited a noticeable ChAT downregulation
which was prevented by VEGF administration. To explore whether this action was
mediated via an increase in blood vessels or in their permeability, we performed
immunohistochemistry against laminin, glucose transporter-1 and the plasmatic protein
albumin. The quantification of the immunolabeling intensity against these three proteins
showed no significant differences between VEGF-treated, axotomized and control
animals. Therefore, the present data indicate that VEGF is able to sustain the cholinergic
phenotype in damaged motoneurons, which is a first step for adequate neuromuscular
neurotransmission, and that this action seems to be mediated directly on neurons since
no sign of angiogenic activity was evident. These data reinforces the therapeutical
potential of VEGF in motoneuronal diseases.
Keywords: VEGF, axotomy, oculomotor system, amyotrophic lateral sclerosis, angiogenesis, laminin, glucose
transporter 1 (GLUT-1), acetylcholine
INTRODUCTION
Vascular endothelial growth factor (VEGF) was initially characterized by its actions on the
vasculature, inducing vasculogenesis, angiogenesis and increased permeability of capillary vessels
(Ferrara and Davis-Smyth, 1997; Yancopoulos et al., 2000). However, evidence has been
accumulating during the last years showing that VEGF also exerts direct effects at the neuronal
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level. For instance, both in vitro and in vivo experiments have
revealed that VEGF acts as a potent neuroprotective molecule
when administered to neurons exposed to different types of
insults, such as hypoxia, ischemia, excitotoxicity or epileptic
seizures (Jin et al., 2000, 2001; Matsuzaki et al., 2001; Lambrechts
and Carmeliet, 2006; Nicoletti et al., 2008; Lange et al., 2016).
In this regard, a great interest in VEGF has emerged after the
recent link established between low levels of this factor and
the motoneuronal neurodegenerative disease amyotrophic lateral
sclerosis (ALS; Oosthuyse et al., 2001; Sathasivam, 2008), a severe
pathology that courses with motoneuronal death and lethality
in a few years subsequent to the onset of the disease (Cleveland
and Rothstein, 2001; Robberecht and Philips, 2013; Turner et al.,
2013).
A crucial study relating VEGF deficit with ALS was obtained
by the design of the mutant mice VEGFδ/δ, in which the
hypoxia response element located in the promoter region of
the VEGF gene was deleted, causing a decrease in VEGF levels
with time that leads to adult-onset motoneuron degeneration
reminiscent of ALS (Oosthuyse et al., 2001). On the other
hand, double-transgenic mice resulting from the cross between
animals overexpressing VEGF and those presenting a well-
accepted model of ALS (superoxide dismutase-1 mutation)
display delayed motoneuronal loss, motor improvement,
and prolonged survival as compared with the superoxide
dismutase-1 mutant mice (Wang et al., 2007). The delivery of
VEGF directly or through viral vectors using different routes
(intramuscular, intracerebroventricular, intrathecal or into the
spinal cord parenchyma) considerably reduces the symptoms
of the disease in murine models of ALS (Azzouz et al., 2004;
Storkebaum et al., 2005; Dodge et al., 2010; Wang et al., 2016)
and also protects motoneurons from excitotoxic-induced
cell death (Tovar-y-Romo et al., 2007; Tovar-y-Romo and
Tapia, 2010). In this respect, an increase in VEGF and its
main receptor (VEGFR-2) has also been described in cerebral
motor cortex and hippocampus of postnatal rats following
glutamate excitotoxic treatment, which could contribute
to neuroprotection mechanisms (Castañeda-Cabral et al.,
2017).
Although all these findings indicate that VEGF is a potent
neuroprotective factor for vulnerable motoneurons after trauma
or disease, nowadays there is lack of information concerning
the functional state in which these rescued motoneurons
remain. A particular issue of interest is whether VEGF-protected
motoneurons continue expressing their neurotransmitter,
acetylcholine, an essential step for neuromuscular transmission
and motor function. It is well-known that axotomized
motoneurons exhibit a downregulation in the expression of
the biosynthetic enzyme of their neurotransmitter, choline
acetyltransferase (ChAT; Navarro et al., 2007). Low expression of
ChAT has also been described in remaining spinal motoneurons
of ALS patients in post-mortem studies, even at early non-
advanced stages (Gillberg et al., 1982; Kato, 1989; Oda,
1999).
Extraocular motoneurons, located in the abducens, trochlear
and oculomotor nuclei of the brainstem, constitute a good model
to analyze this issue. Indeed, we have previously reported that
these motoneurons exhibit a decrease in ChAT content that
reaches its maximum at 7 days post-lesion (Morcuende et al.,
2005), in agreement with other studies (Navarro et al., 2007). It
is important to mention that extraocular motoneurons are more
resistant than other cranial or spinal to degeneration in ALS
(Reiner et al., 1995; Haenggeli and Kato, 2002). However, they
also show signs of degeneration but at later stages of the disease
(Takahashi et al., 1993; Sharma et al., 2011; Kimura et al., 2014;
Tjust et al., 2017).
In the present work, we aimed at evaluating the ability of
exogenously applied VEFG to prevent the loss of the cholinergic
phenotype in lesioned extraocular motoneurons of adult rats.
Moreover, we have recently demonstrated that extraocular
motoneurons express the VEGFR-2, also called Flk1 (Silva-Hucha
et al., 2017), the receptor that mainly mediates the neurotrophic
effects of VEGF (Oosthuyse et al., 2001; Ogunshola et al., 2002;
Brockington et al., 2006; Bogaert et al., 2010; Tovar-y-Romo
and Tapia, 2010; Carmeliet and Ruiz de Almodovar, 2013).
VEGF administration was carried out peripherally through the
proximal stump of the cut nerves innervating the extraocular
muscles, given that this factor can travel retrogradely along
axons toward the soma (Storkebaum et al., 2005). In the present
paper we sought at exploring the angiogenic versus the direct
retrograde neuroprotective action of VEGF in the lesioned
motoneurons.
MATERIALS AND METHODS
Animals and Surgical Procedures
Adult Wistar rats were obtained from an authorized supplier
(University of Seville). All experimental procedures were
performed in accordance with the guidelines of the European
Union (2010/63/EU) and the Spanish legislation (R.D. 53/2013,
BOE 34/11370-421) for the use and care of laboratory animals
and approved by the local committee for ethics in animal research
(Comité Ético de Experimentación de la Universidad de Sevilla).
All efforts were made to minimize the number of animals used
and their suffering in this study.
A total of n = 20 animals were used in the present work: 3
were control non-operated animals, and 17 were lesioned and
treated with either vehicle or VEGF. Animals prepared for lesion
were operated under general anesthesia (sodium pentobarbital,
35 mg/kg, i.p.). Surgery consisted in the enucleation of the left
eye as a method to axotomize extraocular motoneurons, leaving
them also deprived of their target muscles. The procedure for
enucleation has been described in detail previously (Morcuende
et al., 2005, 2011, 2013). Briefly, the left eyeball was extirpated
with the help of a ligature made at the back of the eye
using a suture thread, which also tied the ophthalmic artery
thereby preventing hemorrhage. Intraorbital tissues were also
eliminated and finally we cauterized any bleeding originating
from the orbital space. The orbit was then filled with an
absorbable gelatine sponge pellet (Gelfoam, Pfizer, Belgium)
soaked in either vehicle (20 µl of phosphate-buffer saline,
pH 7.4, PBS, containing 0.1% bovine serum albumin, BSA),
or VEGF (1 µg VEGF prepared in 20 µl of PBS with 0.1%
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BSA). Sham-operated animals, which received only vehicle,
will be referred to as axotomized animals from now onwards.
After the implant, eyelids were accurately sutured. The dose
used for VEGF administration was within the range applied
by other authors (Sun et al., 2003; Manoonkitiwongsa et al.,
2004; Storkebaum et al., 2005; Lambrechts and Carmeliet,
2006; Bogaert et al., 2010). We administered the recombinant
rat VEGF164 aminoacid form that was purchased from R&D
Systems (Minneapolis, MN, United States; 564-RV-050). A total
of n = 5 axotomized and n = 6 VEGF-treated animals
was used for the study of the cholinergic phenotype in
axotomized motoneurons. In addition, we used n = 9 animals
to test the possibility of an angiogenic side-effect induced by
VEGF centrally (3 control, 3 axotomized and 3 treated with
VEGF).
A survival time of 1 week was used since, in a previous work,
we showed that by this time the downregulation in ChAT was
maximal (Morcuende et al., 2005), and also in agreement with
previous studies (reviewed by Navarro et al., 2007). Therefore,
1 week after surgery, animals were perfused intracardially under
deep anesthesia (sodium pentobarbital, 50 mg/kg, i.p.) with
200 ml of physiological saline followed by 400 ml of 4%
paraformaldehyde in PBS. The brainstem was removed, postfixed
for 2 h in the same fixative and cryoprotected in a solution
containing 30% sucrose in PBS until it sank. The brainstem was
then cut coronally at 40 µm thick sections on a cryostat (Leica
CM 1850, Wetzlar, Germany). Sections were kept in the fridge
at −4◦C, immersed in PBS with 0.05% sodium azide, until their
processing.
ChAT Immunostaining
Motoneurons were identified by their immunoreactivity against
ChAT. The primary antibody used was a polyclonal goat
anti-ChAT IgG (1:500, Merck-Millipore, Darmstadt, Germany;
AB-144P). ChAT immunostaining was carried out as follows.
First, brainstem sections were incubated for 10 min in a
solution containing 10% methanol and 2% H2O2 in PBS for
the inactivation of endogenous peroxidase. After washing in
PBS-T (PBS with 0.1% Triton X-100), sections were incubated
for 1 h in the blocking solution containing 3% normal horse
serum in PBS-T. Tissue was then incubated overnight in the
primary antibody solution prepared in PBS-T. After extensive
washing, sections were then transferred to the secondary
antibody solution in PBS-T for 2 h (biotinylated horse anti-goat
IgG, 1:250; Vector Laboratories, Burlingame, CA, United States;
BA-9500). Following rinsing, tissue was incubated for 90 min
in the avidin-biotin-horseradish peroxidase complex (ABC,
Vector Laboratories; PK-6200). Horseradish peroxidase was
revealed using 3, 3′-diaminobenzidine tetrahydrochloride (DAB)
at 0.05% with 0.01% H2O2 diluted in PBS, followed by nickel
intensification of the DAB reaction product by immersing
sections in 0.01 mM nickel ammonium sulfate prepared in
0.05 M TRIS buffer, pH = 8. After stopping the reaction
with PBS, sections were finally mounted on gelatinized glass
slides, dehydrated, cleared in xylene and coverslipped with
DPX mounting medium (Panreac, Barcelona, Spain). For
controls in this and subsequent immunocytochemistries (see
below), we omitted the primary antibody obtaining absence of
labeling.
Evaluation of the Possible Angiogenic
Effect of VEGF
In order to check the possibility that VEFG administration
could mediate its neuronal effects, at least in part, through
its well-known angiogenic activity, we characterized by
immunocytochemistry the structure/function of the vascular
network in the three extraocular motor nuclei, under the different
experimental situations, using the following antibodies (Krum
et al., 2002): (i) a marker of the endothelial basement membrane,
laminin (polyclonal rabbit anti-laminin, 1:200; Sigma-Aldrich,
St. Louis, MO, United States; L 9393); (ii) the glucose transporter
1 (GLUT-1) expressed selectively by endothelial cells of the
blood-brain barrier (mouse monoclonal antibody, 1:1000;
Merck Millipore, Billerica, MA, United States; MAB S 132); and
(iii) the plasmatic protein albumin, as a marker of increased
vascular permeability and leakage indicating dysfunction of the
blood–brain barrier (sheep polyclonal antibody against rat serum
albumin, 1:250; MP Biomedicals, Solon, OH, United States;
55729). Immunoreactivity for these antibodies was carried out in
control (n = 3), axotomized (n = 3) and VEGF-treated (n = 3)
animals and findings compared between the three groups. To
reveal rat serum albumin, a secondary antibody consisting
in a biotinylated donkey anti-sheep IgG (Jackson Immuno
Research West Grove, PA, United States; 713-065-003) was used
at 1:500 following a protocol similar to that carried out for ChAT
detection (see above).
Laminin and GLUT-1 were revealed by immunofluorescence
in combination with ChAT immunolabeling for the location
of the motor nuclei. We performed triple immunofluorescence
of ChAT + laminin + GLUT-1 in sequential steps. Using
10% normal donkey serum as the blocking agent, sections
were incubated in each primary antibody solution (diluted
as indicated above for ChAT, laminin or GLUT-1) and then
in its corresponding secondary antibody solution. Secondary
solutions contained donkey anti-goat IgG conjugated to Cy2
(1:100; 705-225-003) for ChAT labeling, donkey anti-rabbit
IgG conjugated to TRITC for laminin (1:200; 711-025-152),
or donkey anti-mouse IgG conjugated to Cy5 (1:200; 715-175-
150) to reveal GLUT-1. Rinses were carried out as required
with PBS-T, except the last one in which we used PBS.
All cytochemical procedures were carried out in free floating
sections and at room temperature. Secondary antibodies were
obtained from Jackson Immuno Research. After rinsing, sections
were mounted on gelatinized glass slides and coverslipped
with DAKO fluorescent mounting medium S3023 (Glostrup,
Denmark).
Images were captured at the level of the three extraocular
motor nuclei with a confocal laser scanning microscope (Zeiss
LSM 7 DUO; Oberkochen, Germany) using the 40× objective,
in order to analyze and contrast the results obtained between
the different experimental situations and motor nuclei. Series of
focal planes of 2 µm virtual thickness were captured through the
regions of interest. Z-stacks were generated after overlapping 6
focal planes of the same histological section by using the Zeiss
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imaging software ZEN. Analysis was carried out on the z-stacks
obtained after laminin or GLUT-1 immunostaining. Images
were generated in three different fluorescence channels with the
following excitation wavelengths: 488 nm for Cy2 (green), 561 nm
for TRITC (red), and 633 nm for Cy5 (white).
Quantification of ChAT Immunostaining
in Motoneurons
To count the number of motoneurons, we used the 40-
µm transverse brainstem sections labeled with the anti-ChAT
antibody. We estimated by stereological methods the number of
ChAT-positive cells in the abducens, trochlear and oculomotor
nuclei using the optical fractionator method (Golub et al., 2015)
by means of the newCAST stereological software (Visiopharm,
Hoershold, Denmark) adapted to an Olympus BX61 microscope
(Hicksville, NY, United States). Countings were performed at
both the left and right sides of each nucleus in axotomized
(n = 5) as well as VEGF-treated (n = 6) animals. The principle
of Cavalieri was used to estimate the volume of the extraocular
nuclei. The number of neurons in the analyzed region was
estimated by multiplying the number of neurons counted within
the sample regions by the reciprocals of the volume sampling
fraction (De Pablos et al., 2014). Data were normalized per
nucleus and animal and expressed as percentage values relative
to the control side.
Since abducens motoneurons project ipsilaterally and superior
oblique motoneurons contralaterally to their corresponding
extraocular muscles, then the affected side of the abducens and
trochlear nuclei was the left and the right side, respectively,
after left eye enucleation. The oculomotor nucleus contains
four motoneuronal subdivisions (three project ipsilaterally and
one contralaterally) with a similar number of motoneurons
per subdivision (Glicksman, 1980; Miyazaki, 1985; Evinger,
1988). Therefore, for ChAT countings, we applied a correction
as previously described (Morcuende et al., 2005, 2011, 2013)
to consider the left oculomotor nucleus as the affected one.
Briefly, we solved the following equation: 3x + y = n1 and
3y + x = n2, where n1 and n2 are the number of oculomotor
motoneurons ipsilateral and contralateral, respectively, to the
lesion side (left). Therefore, we calculated x and y, where x
is the number of motoneurons per lesioned subnucleus (three
subdivisions ipsilateral and one contralateral) and y is the number
of motoneurons per control subnucleus.
We also quantified the intensity of ChAT immunostaining.
We measured the mean gray value (optical density) of the
motoneurons in the three nuclei, at both sides, and in the
two experimental groups (i.e., axotomized and VEGF-treated)
by means of the Image J program (NIH, Bethesda, MD,
United States). The outline of each ChAT-positive motoneuron
within the limits of each nucleus was traced (the cell nucleus
excluded), and the program gave the mean gray value per cell
(intensity of cell immunostaining). To normalize data among
different sections, cell values were divided by the background
level obtained in the same section. Finally, data were normalized
per nucleus and animal, and expressed as percentage values
relative to the control side.
Quantification of Blood Vessel
Immunostaining and Vascular
Permeability
The analysis of laminin and GLUT-1 optical density in the
abducens, trochlear and oculomotor nuclei, was carried out
using the z-stacks described above, generated by the confocal
microscope software. The boundaries of the three motor
nuclei were determined by the ChAT immunolabeling. Images
were analyzed with the help of the Image J program. For
measurements, a grid was elaborated consisting in squares of
10 µm × 10 µm spaced every 10 µm. Within each square
we measured the mean gray value, excluding those containing
a ChAT-immunopositive cell. Only those squares showing
an optical density value higher than 0.1, after background
subtraction, were computed for the analysis. Then we calculated
the percentage of 10 µm × 10 µm squares whose optical density
was higher than 0.1 in relation to the total number of squares
counted per section. Data were measured in control (n = 3),
axotomized (n = 3), and VEGF-treated (n = 3) animals on the
affected side of each nucleus or, in the case of control animals,
on the left side. For axotomy and VEGF treatment, data were
normalized per nucleus and animal, and expressed as percentage
relative to the control animals.
Since GLUT-1 labels mature endothelial cells (Krum et al.,
2002), we also quantified the area in those blood vessels that
were laminin-immunopositive but GLUT-1-immunonegative, as
a likely index of newly-formed vessels, by outlining the region
of interest with the help of the program Image J. This analysis
was performed in the triple immunofluorescence sections within
the limits of each motor nucleus, identified by the ChAT
immunostaining. Data were measured in control (n = 3),
axotomized (n = 3), and VEGF-treated (n = 3) animals on the
affected side of each nucleus or, in the case of control animals,
on the left side. Finally, data were normalized per nucleus and
animal, and expressed as percentage values relative to the control
animals.
In the case of albumin immunostaining, we also measured the
optical density (with the help of the Image J program) in the
affected side of each motor nucleus for the axotomized (n = 3) and
VEGF-treated animals (n = 3), as well as in the left side for control
intact animals (n = 3). Optical density was compared between
control, axotomized or VEGF-treated nuclei.
Statistics
Data were represented as the mean and standard error of the
mean (SEM). The number of ChAT-positive cells as well as
the intensity of the different immunostainings were compared
between the different extraocular motor nuclei (factor 1) and
experimental situations (factor 2). To detect differences between
groups, the two-way ANOVA test was used at an overall level
of significance of 0.05 followed by the post hoc Holm–Sidak
method for all pairwise multiple comparisons. When required,
we also used the paired t-test for comparisons between the two
sides of the same nucleus. Statistics was performed by using
the program SigmaPlot 11 (Systat Software, Inc., Chicago, IL,
United States).
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FIGURE 1 | Vascular endothelial growth factor (VEGF) prevents the loss of the cholinergic phenotype in lesioned extraocular motoneurons. Images of coronal
sections through the abducens (ABD), trochlear (TRO), and oculomotor (OCM) nuclei of axotomized animals treated with either vehicle (A–C), or VEGF (D–F).
Sections were immunostained against ChAT, the biosynthetic enzyme of the motoneuronal neurotransmitter acetylcholine. The affected side of each nucleus is
indicated by an arrowhead at the top of (A–C). Note the marked reduction in the number of ChAT-immunolabeled motoneurons in the affected side of axotomized
animals as compared with their respective control side (A–C). In contrast, VEGF administration maintained, in the axotomized side, a number of
ChAT-immunostained motoneurons similar to the control side (D–F; compare control with treated side). Scale bars = 200 µm. (G) Bar chart illustrating the number of
ChAT-positive motoneurons in axotomized (black) and VEGF-treated (gray) animals for the three extraoculomotor nuclei (ABD, abducens; TRO, trochlear; OCM,
oculomotor) expressed as the percentage of immunostained motoneurons in the affected side relative to the control side. The horizontal dashed line indicating 100%
refers to the control side of each nucleus, used to normalize data (∗p < 0.05, significant differences with respect to the control side, paired t-test). Note that the
number of ChAT-immunoreactive motoneurons was significantly higher in VEGF-treated animals as compared to axotomized animals (treated with vehicle) for ABD,
TRO, and OCM. In turn, no significant differences were found between these nuclei irrespective of the treatment. Two-way ANOVA (factor 1, nucleus; factor 2,
treatment) followed by Holm–Sidak method for all pairwise multiple comparisons. #p < 0.05, significant differences between axotomy and VEGF treatment. Data
represent mean and SEM; n = 5 axotomized and n = 6 VEGF-treated animals for each nuclei.
RESULTS
Axotomized Extraocular Motoneurons
Exhibit a Downregulation in ChAT
Expression
The axonal section of extraocular motoneurons performed at the
orbital level led to a noticeable decrease in the immunostaining
against ChAT in the corresponding brainstem motor nuclei
(abducens, trochlear, and oculomotor). The examination of the
immunostained sections clearly showed that the number of
ChAT-positive motoneurons in the lesioned side of these nuclei
(arrowhead in Figures 1A–C) was markedly lower than that
observed in their respective control side. Thus, the number
of stained cells fell to 66.74 ± 1.89%, 53.48 ± 6.45%, and
44.83± 10.56% (with respect to the control side) in the abducens,
trochlear, and oculomotor nuclei, respectively, 1 week after lesion
(Figure 1G). The statistical comparison of the number of ChAT-
immunoreactive motoneurons between the control and the
axotomized side revealed significant differences in the abducens
(p < 0.001, paired t-test), trochlear (p = 0.021, paired t-test) and
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oculomotor (p = 0.01, paired t-test) nuclei (n = 5 animals), in all
cases with a significantly lower number of ChAT-immunoreactive
motoneurons in the axotomized side (Figure 1G, asterisks).
We also observed that ChAT immunolabeling in the
axotomized side showed, in comparison with the control side,
not only a fewer number of labeled cells but also the presence
of weakly-stained motoneurons, so that the affected side was
characterized by a faint staining (Figures 2D–F) that markedly
contrasted with the strong labeling present in the control side
(Figures 2A–C). For this reason, we also quantified the intensity
of immunolabeling by measuring the optical density within
the cytoplasm of ChAT-positive motoneurons and expressed
data as percentage relative to the control side. In axotomized
animals, the optical density of ChAT immunolabeling decreased
to 72.21 ± 1.94%, 76.90 ± 1.94%, and 77.89 ± 1.43% (as
compared to the control side; n = 5) in the abducens, trochlear
and oculomotor nuclei, respectively. The statistical comparison
of the intensity of ChAT immunostaining between the control
and the axotomized side revealed significant differences in the
abducens (p = 0.001, paired t-test), trochlear (p < 0.001, paired
t-test), and oculomotor (p < 0.001, paired t-test) nuclei (n = 5
animals), with a significantly lower level of ChAT intensity in the
axotomized side of the three nuclei (Figure 2J, asterisks).
Therefore, axotomy produced a significant decrease in both
the number of ChAT-immunoreactive motoneurons and the
intensity of ChAT immunostaining.
VEGF Administration Prevents the
Downregulation Exhibited by
Axotomized Motoneurons
An interesting finding of the present work was that treatment
with VEGF at the time of axotomy prevented the reduction in
ChAT immunostaining caused by lesion, so that the affected side
(axotomized plus VEGF-treated) appeared with a similar number
of ChAT-immunolabeled motoneurons as compared with the
control side (Figures 1D–F). The statistical analysis confirmed
our observations revealing absence of significant differences in
the abducens, trochlear, and oculomotor nuclei between the
treated versus the control side for those animals that received
the VEGF intraorbital implant (paired t-tests; Figure 1G,
n = 6). Furthermore, we also compared the percentages
of ChAT-positive motoneurons in the affected side between
axotomized and VEGF-treated animals after normalization to
their respective control side (two-way ANOVA test followed
by Holm–Sidak method for post hoc comparisons; Figure 1G).
VEGF treatment showed a significantly higher percentage
of ChAT-immunoreactive motoneurons (93.16 ± 14.94% for
abducens, 97.61 ± 15.14% for trochlear, and 83.77 ± 13.49%
for oculomotor) than in the axotomy condition (see above
the axotomy percentages; p < 0.05; Figure 1G, hashtag,
compare gray columns with black columns). In turn, there
were no significant differences between nuclei irrespective of
treatment.
Vascular endothelial growth factor also protected
motoneurons against the decrease in the level of ChAT
immunostaining induced by lesion. Thus, motoneurons of
VEGF-treated animals (Figures 2G–I) appeared markedly-
stained in a similar way to those of the control side
(Figures 2A–C). Indeed, we obtained statistical similarity
regarding ChAT intensity in the abducens, trochlear, and
oculomotor nuclei between the VEGF-treated versus the
control side (Figure 2J, paired t-tests; n = 6). Furthermore, we
compared the percentages of ChAT immunostaining intensity
in motoneurons of the affected side between axotomized and
VEGF-treated animals after normalization to their respective
control side (two-way ANOVA test followed by Holm–Sidak
method for post hoc comparisons; Figure 2J). VEGF treatment
produced a significantly higher percentage of ChAT optical
density (98.58 ± 1.43% for abducens, 98.33 ± 1.37% for
trochlear, and 99.01 ± 1.12% for oculomotor) than in the
axotomy condition (see above the axotomy percentages;
p < 0.05; Figure 2J, hashtag, compare gray columns with black
columns). The test also revealed absence of significant differences
between abducens, trochlear, and oculomotor nuclei irrespective
of treatment.
Therefore, these data confirmed that VEGF delivery to injured
motoneurons protected them against the downregulation in
ChAT expression, in regard to both the number of ChAT-positive
motoneurons and the intensity of ChAT immunostaining.
The Neuronal Effects Mediated by VEGF
Were Not Associated to an Angiogenic
Response
Due to the well-known effects of VEGF on the vasculature,
including angiogenesis and increased vascular permeability, we
aimed at elucidating whether the effects found at the neuronal
level after VEGF administration could be explained by its action
on the vascular system, that is, providing more nutrients and
oxygen to the affected motoneurons and in this way promoting
neuroprotection or, alternatively, whether VEGF might act
directly on neurons. For this purpose, and in accordance with
previous studies (Oosthuyse et al., 2001; Krum et al., 2002;
Azzouz et al., 2004), we performed an immunohistochemical
study against the following antigens: (i) albumin, a plasmatic
protein used as an index of vascular leakage induced by increased
permeability; (ii) laminin, as a marker of the basement membrane
of blood vessels; and (iii) GLUT-1, for the specific labeling of
endothelial cells. In these experiments we used three different
groups of experimental animals: (i) intact, untreated, controls
(n = 3); (ii) axotomized and treated with vehicle (n = 3; axotomy
condition); and (iii) axotomized but treated with VEGF (n = 3;
VEGF condition).
The immunostaining of albumin was carried out at the light
microscopy level in the different extraocular motor nuclei and
situations using DAB as the chromogen. The visualization of
sections revealed in all cases a very faint and diffuse staining
that did not label any particular element within the tissue
(Figures 3A–C, abducens nucleus illustrated). The measurements
of optical density in each nucleus after albumin immunostaining
revealed that there were no significant differences between
either the different nuclei or situations (Figure 3D, two-way
ANOVA test followed by Holm–Sidak method for post hoc
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FIGURE 2 | Vascular endothelial growth factor maintains a normal intensity of ChAT immunostaining in axotomized motoneurons. (A–C) ChAT immunolabeling in the
control side of the abducens (A, ABD; right side), trochlear (B, TRO; left side) and oculomotor (C, OCM; right side) nuclei. (D–F) Same as (A–C) but for the lesioned
side (D, left ABD; E, right TRO; F, left OCM) of an axotomized animal. (G–I) Same as (D–F) but for a VEGF-treated animal. Note the presence of faintly-labeled cells
in the axotomized size (D–F) of lesioned animals (arrowheads). In contrast, ChAT immunoreactive-cells in VEGF-treated animals (G–I) showed a staining intensity
similar to control (A–C). Scale bars = 100 µm. (J) Bar chart illustrating the percentage of ChAT immunostaining intensity in motoneuron cell bodies of axotomized
(black columns) and VEGF-treated (gray columns) animals for the three extraoculomotor nuclei (ABD, TRO and OCM), expressed as the percentage of ChAT labeling
intensity in the affected side with respect to the control side. The horizontal dashed line at 100% level refers to the control side of each nucleus, used for
normalization of data (∗p < 0.01, significant differences with respect to the control side, paired t-test). Note that the intensity of ChAT-immunoreactive motoneurons
was significantly higher in VEGF-treated animals as compared to axotomized animals (treated with vehicle) for ABD, TRO, and OCM. In turn, no significant
differences were found between ABD, TRO, and OCM irrespective of the treatment. Two-way ANOVA (factor 1, nucleus; factor 2, treatment) followed by Holm–Sidak
method for all pairwise multiple comparisons. #p < 0.05, significant differences between axotomy and VEGF treatment. Data represent mean and SEM. n = 5
axotomized and n = 6 VEGF-treated animals for each nuclei.
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FIGURE 3 | Vascular endothelial growth factor administration does not
produce vascular leakage as revealed by rat serum albumin immunostaining.
Images of coronal sections through the abducens nucleus showing virtually
absence of albumin immunoreactivity in the three experimental situations: (A),
control intact animal; (B), axotomized animal treated with vehicle; and (C),
axotomized animal treated with VEGF. Arrowheads in (B,C) point to the
affected (axotomized) side. The dashed lines in (A–C) label the boundaries of
the abducens nucleus. VIIg, genu of the facial nerve. Scale bar = 200 µm.
(D) Bar chart illustrating the measurements of albumin immunolabeling in the
different experimental situations (control, axotomized and VEGF-treated
animals) and for the three extraocular motor nuclei (ABD, abducens; TRO,
trochlear; and OCM, oculomotor nuclei). Data represent mean ± SEM and are
expressed relative to the control animals (100%, horizontal dashed line).
Comparisons were carried out by means of the two-way ANOVA test at a level
of significance of p < 0.05. Note absence of significant differences between
nuclei and treatments. n = 3 animals in each situation and nucleus.
comparisons). Therefore, our data of albumin immunolabeling
suggested absence of significant increase in vascular permeability
due to VEGF treatment.
For the study of laminin, we used the triple
immunofluorescence sections (see section “Materials and
Methods”) focusing on ChAT (in green) and laminin (in
red). ChAT labeling was used to delimit the three motor
nuclei of interest (see example for the oculomotor nucleus in
Figures 4A,D,G for the control, axotomy and VEGF situations,
respectively). The immunostaining against laminin yielded a very
conspicuous signal outlining clearly the blood vessels throughout
the histological sections in the different experimental conditions
(Figures 4B,E,H). For the analysis, only those laminin-positive
elements located within the limits of the nuclei outlined by the
ChAT immunolabeling were considered (see merged images
in Figures 4C,F,I). Using a grid (see section “Materials and
Methods” for more details) we quantified the immunoreactivity
against laminin in the abducens, trochlear and oculomotor nuclei
for the control, axotomy and VEGF conditions. Axotomy and
VEGF data were expressed as percentages relative to the control
animals. For instance, in the case of the abducens nucleus, data
were 100 ± 14.30%, 81.80 ± 18.16%, and 81.84 ± 8.19% for
control, axotomized and VEGF-treated animals, respectively
(n = 3 in each situation). As observed in Figure 4J, no significant
differences were found in laminin immunostaining between
either experimental conditions or motor nuclei (two-way
ANOVA test).
We also analyzed the selective marker of endothelial cells
GLUT-1 in the triple immunofluorescence sections, according
to the same procedure as described above for laminin. GLUT-
1 (in white) was analyzed within the limits of the three
extraoculomotor nuclei defined by the ChAT labeling (in
green) and in the three experimental situations (control,
axotomized, or VEGF-treated animals; n = 3 in each case).
An example of GLUT-1 immunostaining for the oculomotor
nuclei in the three situations is illustrated in Figures 5A–I. For
quantification, data were normalized with respect to control
animals (e.g., 100 ± 3.7%, 85.36 ± 18.99%, and 91.64 ± 12.24%
for the abducens nucleus in control, axotomy and VEGF
situations, respectively; n = 3 in each case). Comparison of
the degree of GLUT-1 immunolabeling also revealed absence
of significant differences between the different experimental
conditions as well as between the different motor nuclei (two-
way ANOVA test, Figure 5J). Altogether, the laminin and
GLUT-1 data obtained in the present work pointed to absence
of angiogenesis around the motoneurons following VEGF
administration.
Since GLUT-1 labels mature endothelial cells (Krum
et al., 2002), we performed another analysis in the triple
immunostained sections consisting in the measurement of
the area of those laminin-outlined blood vessels which lacked
any associated GLUT-1 immunostaining (Figure 6), assuming
that these structures could possibly represent immature newly-
formed vessels (arrowheads in Figures 6C,F,I). We carried out
the analysis in the abducens, trochlear and oculomotor nuclei of
control, axotomized and VEGF-treated animals (n = 3 animals
in each situation). The statistical analysis of laminin-positive,
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FIGURE 4 | Laminin immunostaining reveals absence of VEGF-induced angiogenesis. Confocal microscopy images of coronal sections through the oculomotor
nucleus against ChAT and laminin showing absence of angiogenesis after VEGF administration. (A–C) Control intact animal. (D–F) Axotomized animal treated with
vehicle. (G–I) Axotomized animal treated with VEGF. Arrowheads point to the affected (axotomized) side in (D–I). Motoneurons were identified as
ChAT-immunoreactive (A,D,G, in green). Laminin was used as a marker of blood vessels (B,E,H, in red). The merged images of ChAT and laminin are illustrated in
(C,F,I). Note a similar density of laminin-labeled blood vessels surrounding motoneurons in the three experimental situations. Scale bars = 100 µm. (J) Bar chart
illustrating the measurements of laminin immunoreactivity in the different experimental situations (control, axotomized, and VEGF-treated animals) and for the three
extraocular motor nuclei (ABD, abducens; TRO, trochlear; and OCM, oculomotor nuclei). Data represent mean ± SEM and are expressed relative to the control
animals (100%, horizontal dashed line). Comparisons were carried out by means of the two-way ANOVA test at a level of significance of p < 0.05. Note absence of
significant differences between nuclei and treatments. n = 3 animals in each situation and nucleus.
GLUT-1 negative areas, normalized to control, revealed that
there were no significant differences in the values obtained
between either the different experimental situations or the three
motor nuclei (two-way ANOVA test). These findings reinforce
those obtained after the analysis of laminin and GLUT-1 carried
out independently (see above). Therefore, according to the
findings obtained with all vascular markers used in the present
work (albumin, laminin and GLUT-1), it might be propose
that VEGF, at this dose, did not induce in the extraoculomotor
nuclei any increase in the vascular network or in permeability
that could support the neuroprotective effect exerted by this
factor on the cholinergic phenotype of severed motoneurons.
Accordingly, our data point to a direct action of VEGF on
neurons.
DISCUSSION
The present work has demonstrated that the exogenous
administration of VEGF is able to maintain injured motoneurons
with a normal level of ChAT, the biosynthetic enzyme of
their neurotransmitter acetylcholine, thereby preventing the
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FIGURE 5 | GLUT-1 immunostaining reveals absence of VEGF-induced angiogenesis. Confocal images of transverse sections through the oculomotor nucleus after
double immunofluorescence against ChAT and GLUT-1. (A–C) Control intact animal. (D–F) Axotomized animal treated with vehicle. (G–I) Axotomized animal treated
with VEGF. Arrowheads point to the affected (axotomized) side in (D–I). Motoneurons were identified as ChAT-immunoreactive (A,D,G, in green). GLUT-1 was used
as a marker of endothelial cells (B,E,H, in white). The merged images of ChAT and GLUT-1 are illustrated in (C,F,I). Note a similar density of GLUT-1-labeled
endothelial cells of blood vessels around motoneurons in the three experimental situations. Scale bars = 100 µm. (J) Bar chart illustrating the measurements of
GLUT-1 immunoreactivity in the different experimental situations (control, axotomized and VEGF-treated animals) and for the three extraocular motor nuclei (ABD,
abducens; TRO, trochlear; and OCM, oculomotor nuclei). Data represent mean ± SEM and are expressed relative to the control animals (100%, horizontal dashed
line). Comparisons were carried out by means of the two-way ANOVA test at a level of significance of p < 0.05. Note absence of significant differences between
nuclei and treatments. n = 3 animals in each situation and nucleus.
downregulation in ChAT that ensues motoneuronal lesion. The
fact that ChAT can be maintained in axotomized VEGF-treated
motoneurons likely implies a normal level of the motoneuronal
neurotransmitter acetylcholine. Consequently, this finding is
of great interest since it would imply that VEGF can sustain
lesioned motoneurons in an operational state, at least regarding
the synthesis of neurotransmitter as a first step necessary
for neuromuscular transmission. Therefore, our data strongly
support the potentiality of VEGF as a therapeutic tool for
the treatment of motoneuronal diseases, reinforcing previous
findings showing that this factor can prevent motoneuronal
death in animal models of ALS (Azzouz et al., 2004; Storkebaum
et al., 2005; Wang et al., 2007; Sathasivam, 2008). The present
data add the possibility that this factor might also maintain
surviving motoneurons in a neurotransmissive mode. Moreover,
our evaluation of the vasculature and capillary permeability
in the extraocular motor nuclei indicated that the neuronal
effects mediated by VEGF are likely the consequence of a
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FIGURE 6 | Labeling of blood vessels showing absence of angiogenic response to VEGF treatment. (A,D,G) Laminin immunostaining (in red) of the basement
membrane of blood vessels in control (A), axotomized (D), and VEGF-treated (G) animals. (B,E,H) Same as (A,D,G) but for GLUT-1 immunolabeling of endothelial
cells (in white). The merged images of both markers are shown in (C,F,I) for control (C), axotomy (F) and VEGF treatment (I). Note similarity in blood vessel labeling in
the three situations for the two markers. White arrowheads in (C,F,I) point to blood vessels which were laminin-immunopositive but GLUT-1-immunonegative,
suggestive of newly formed vascular sprouts in the three situations. All images shown correspond to the oculomotor nucleus. Scale bar = 100 µm. (J) Bar chart
illustrating the percentage of the area of blood vessels that was laminin-immunopositive but GLUT-1-immunonegative for the different experimental situations
(control, axotomized, and VEGF-treated animals) and for the three extraocular motor nuclei (ABD, abducens; TRO, trochlear; and OCM, oculomotor nuclei). Data
represent mean ± SEM and are expressed relative to the control animals (100%, horizontal dashed line). Comparisons were carried out by means of the two-way
ANOVA test at a level of significance of p < 0.05. Note absence of significant differences between nuclei and treatments. n = 3 animals in each situation and nucleus.
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direct action of this factor on the motoneurons, rather than
an indirect effect mediated by the angiogenic activity of
VEGF.
ChAT Expression Is Downregulated in
Motoneurons After Lesion or Disease
A general phenomenon described in motoneurons following
axotomy is ChAT downregulation. Previous studies in
hypoglossal, facial and spinal motoneurons have shown
that, after nerve lesion, damaged motoneurons lose their
immunoreactivity for ChAT and express low levels of the
transcript (Yan et al., 1994; Friedman et al., 1995; Tuszynski
et al., 1996; Matsuura et al., 1997; Wang et al., 1997). We have
also reported previously the loss of the cholinergic phenotype
in extraocular motoneurons after axotomy, both in adult and
neonatal rats, with the difference that motoneurons finally
die after axotomy in the case of postnatal animals but they
survive in adulthood (Morcuende et al., 2005, 2013). ChAT
downregulation reaches its maximum by 7 days postlesion,
for the motoneurons of the three extraocular motor nuclei
(Morcuende et al., 2005). For this reason we performed the
present work at the time point when lesion-induced effects on
ChAT expression were maximum, in order to determine whether
VEGF administration could be effective in the most drastic
conditions.
Injured motoneurons not only exhibit a downregulation
in ChAT but also many other metabolic, biochemical, and
morphophysiological changes (Titmus and Faber, 1990; Navarro
et al., 2007; Allodi et al., 2012). For instance, whereas molecules
related with neurotransmission decrease, cytoskeleton and
structural proteins increase. These changes has been interpreted
as a switch in motoneuron function from a neurotransmissive
role to a regenerative mode after their lesion (Moran and Graeber,
2004; Morcuende et al., 2005, 2013; Navarro et al., 2007).
It is important to point out that ChAT immunoreactivity is
also markedly reduced in large spinal neurons in ALS cases (Oda
et al., 1995). In addition, the activity and mRNA of this enzyme
are also decreased in patients with ALS (Nagata et al., 1982; Virgo
et al., 1992). Indeed, preserved neurons in the anterior horn of
ALS spinal cord from early non-advanced stages of the disease
show a lower ChAT activity than control neurons (Kato, 1989),
whereas there are no changes in other proteins (Clark et al., 1990).
All these findings have raised the suggestion that low expression
of ChAT is a specific and early change in the pathogenesis of ALS
(Oda, 1999).
VEGF Sustains the Cholinergic
Phenotype in Damaged Motoneurons
The present results have demonstrated that VEGF administered
exogenously immediately after lesion is able to prevent the
loss of the cholinergic phenotype in axotomized motoneurons
by inhibiting the drop in the levels of the enzyme ChAT,
and hence, probably, allowing motoneurons to synthetize their
neurotransmitter acetylcholine. Moreover, we found similar
results in the three extraocular motor nuclei (i.e., abducens,
trochlear, and oculomotor).
The finding that VEGF maintains the level of ChAT
expression in damaged motoneurons likely reflects a normal
synthesis of acetylcholine in the motoneurons, which would
be of great functional relevance for the proper neuromuscular
communication. As stated above, several experiments have
demonstrated that the administration of VEGF may alleviate
motoneuronal degeneration in ALS animal models (Azzouz et al.,
2004; Storkebaum et al., 2005; Tovar-y-Romo et al., 2007; Dodge
et al., 2010; Tovar-y-Romo and Tapia, 2010) and that ChAT is
also downregulated in ALS patients (Nagata et al., 1982; Kato,
1989; Clark et al., 1990; Virgo et al., 1992; Oda et al., 1995; Oda,
1999). According to those data and our present findings, the
possibility exists that VEGF applied to diseased motoneurons
not only rescues them from cell death but also maintains their
neurotransmissive phenotype.
Previous studies have shown that other neurotrophic factors
are also able to prevent the loss of the cholinergic phenotype
in axotomized motoneurons. Thus, we have previously applied
brain-derived neurotrophic factor, nerve growth factor, glial cell-
line-derived neurotrophic factor or neurotrophin-3 to neonatal
rats enucleated at postnatal day 0, using the same procedures as
in the present work. The results obtained showed that all these
factors rescue postnatal axotomized motoneurons from cell death
and that all, except NT-3, also prevent the reduction in ChAT
subsequent to axotomy (Morcuende et al., 2013). In addition
to extraocular motoneurons, other types of motoneurons are
also protected from the lesion-induced loss of ChAT after the
administration of different neurotrophic factors (Yan et al.,
1994, 1995; Friedman et al., 1995; Tuszynski et al., 1996; Wang
et al., 1997; Fernandes et al., 1998; Sakamoto et al., 2003; Zhao
et al., 2004). However, although these other molecules have
also shown the capability to prevent the downregulation in
ChAT, or other aspects of motoneuron physiology, their lack
does not cause adult-onset ALS-like motoneuron degeneration
and paralysis in mice, as happens for VEGF (Oosthuyse et al.,
2001; Lambrechts and Carmeliet, 2006; Gould and Oppenheim,
2011; Tovar-y-Romo et al., 2014). In addition, VEGF is
probably the most potent among all neurotrophic factors tested
in experimental ALS models (Gould and Oppenheim, 2011;
Tovar-y-Romo et al., 2014) and the only one showing an
evident relationship between low levels of the factor (and/or
its main receptor VEGFR-2) and motoneuron degeneration,
as shown in both animal models and human cases of ALS
(Oosthuyse et al., 2001; Brockington et al., 2006; Sathasivam,
2008).
Recently, we have shown that the administration of VEGF to
axotomized abducens motoneurons in cats prevents and recovers
the discharge characteristics and synaptic complement that are
typically affected by lesion (Calvo et al., 2018). Together with the
present data, indicating the maintenance of the neurotransmitter
biosynthetic enzyme in VEGF-treated axotomized extraocular
motoneurons, it can be suggested that VEGF likely acts as an
important, crucial neurotrophic factor for motoneurons of the
oculomotor system. This assumption can be extended to other
motoneuronal types, given that the deficit in VEGF present in
the mutant mice VEGFδ/δ leads to motoneuron degeneration in
the spinal cord (Oosthuyse et al., 2001). Altogether, it seems that
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VEGF could be also a powerful neurotrophic factor for other
non-extraocular motoneurons.
Evidences of Direct Versus Angiogenic
Effects of VEGF on Motoneurons
Two mechanisms have been proposed to explain the
neuroprotective action of VEGF on neurons exposed to
different types of insult or disease (Oosthuyse et al., 2001;
Carmeliet and Storkebaum, 2002; Storkebaum et al., 2004;
Lange et al., 2016). First, due to its well-known activity on blood
vessels, the promotion of vascular proliferation and permeability,
a likely mechanism of action for exogenously applied VEGF,
could lead to an increased vascular perfusion within the neural
tissue, providing an extra supply of oxygen and nutrients to
neurons which would contribute to their recovery. The second
possibility is that VEGF acts directly on neurons activating
signaling pathways that finally lead to the neuroprotective
effects described for this factor. Both mechanisms could indeed
coexist (Oosthuyse et al., 2001; Carmeliet and Storkebaum, 2002;
Storkebaum et al., 2004; Lange et al., 2016).
There is considerable evidence in favor of a direct, receptor-
mediated, protective action of VEGF on neurons (Jin et al.,
2001; Matsuzaki et al., 2001; Azzouz et al., 2004; Tovar-y-Romo
et al., 2007; Nicoletti et al., 2008; Tovar-y-Romo and Tapia,
2010; Lladó et al., 2013) and some works describe absence of
vascular effects after VEGF exogenous administration (Azzouz
et al., 2004; Tovar-y-Romo et al., 2007; Nicoletti et al., 2008).
On the other hand, some studies have revealed that VEGF can
induce angiogenesis (Krum et al., 2002) or increased permeability
(Croll et al., 2004) and that its deficit can lead to decreased neural
vascular perfusion (Oosthuyse et al., 2001). Therefore, since there
is not at present a clear consensus on the possibility of vascular
effects following VEGF administration, we were interested in
evaluating a possible angiogenic response in our model that could
mediate the VEGF-induced ChAT recovery.
In the present work, we have used laminin as a marker of
the basement membrane of blood vessels and GLUT-1 as a
specific marker of endothelial cells to analyze whether VEGF
administration could promote abnormal growing of vascular
structures that could supply more oxygen and nutrients to the
affected motoneurons. Moreover, since VEGF also increases
vascular permeability, we have also used albumin to check the
possibility of extravascular leakage. These markers have also been
used previously by other authors (Oosthuyse et al., 2001; Krum
et al., 2002; Azzouz et al., 2004). Our data have shown that
the intensity of immunostaining against laminin and GLUT-1
in the affected side of the abducens, trochlear, and oculomotor
nuclei was similar in the axotomized animals, treated either
with vehicle or VEGF, as compared to the control group (intact
animals). The same result was obtained with the analysis of
albumin immunolabeling. However, regarding albumin, it should
be pointed out that, due to its high molecular weight, it might be
not suitable for detecting small fluid leakage. Nevertheless, and
in agreement with previous works (Oosthuyse et al., 2001; Krum
et al., 2002; Azzouz et al., 2004), our findings showed that the
administered VEGF was not accompanied by either angiogenesis
or a significantly increased vascular permeability around treated
motoneurons. Therefore, it could be assumed that the action of
this factor on ChAT expression was likely due to a direct effect on
the motoneurons, instead of an indirect effect due to increased
blood perfusion.
Since GLUT-1 labels mature endothelial cells (Krum et al.,
2002), we also quantified those regions of blood vessels, identified
as laminin-immunoreactive, which lacked GLUT-1 labeling, as
likely indicative of newly-formed vessels. Our analysis also
revealed absence of differences between the three groups (control,
axotomized, and VEGF-treated animals), which seems to indicate
again that VEGF administration did not activate angiogenesis in
the tissue surrounding extraocular motoneurons, in agreement
with previous data using the same procedure (Krum et al., 2002).
It is important to stand out that the differences found in the
literature regarding vascular versus neuronal effects following
VEGF exogenous application could be due to two major factors.
First of all, the dose employed might contribute to vascular effects
when VEGF is applied at high doses. Thus, a dose-dependent
study in ischemic rat brain has shown that low (2 µg/7 days) and
intermediate (8 µg/7 days) doses of VEGF are not followed by
angiogenesis, whereas a high dose (60 µg/7 days) does induce a
powerful angiogenic response (Manoonkitiwongsa et al., 2004).
Since we used a Gelfoam implant containing 1 µg of VEGF
that was left in situ by 7 days, our dose was at the lower
range of the dosages used by Manoonkitiwongsa et al. (2004).
Moreover, those authors applied VEGF through the internal
carotid, which represents a more specific and direct route of
delivery as compared with our Gelfoam pellet implant applied
peripherally in the enucleated orbit; therefore our “effective”
VEGF dose reaching the brainstem was likely lower. The second
factor that could influence an angiogenic VEGF-mediated activity
is the pathway of administration. Thus, Krum et al. (2002) have
described a higher vascular proliferation in adult rat brain using
intracerebral osmotic minipump than after the less traumatic
subdural gelatine sponge placement. In the present work,
we applied VEGF from the periphery (intraorbitally) without
interfering with the integrity of the central nervous system and,
therefore, reducing the risk of promoting angiogenic activity in
the brain. Indeed, we have previously shown that extraocular
motoneurons express the receptor VEGFR-2 in rats (Silva-Hucha
et al., 2017; VEGFR-1 not tested), and in the cat the two
receptors VEGFR-1 and VEGFR-2 are present (Calvo et al., 2018).
Moreover, VEGF has been previously shown to be retrogradely
transported along axons (Storkebaum et al., 2005). Therefore,
given that in our study VEGF was administered through a
gelatine sponge implanted into the orbit after enucleation, this
factor likely reached motoneurons through retrograde transport
from the proximal stumps of sectioned extraoculomotor axons
and not through the vasculature surrounding motoneurons.
Summing up, the dose and experimental procedure that we
used for VEGF delivery were in the direction of minimizing
any vascular action of VEGF in the brain. Moreover, the
quantification of vascular vessels, endothelial cells and albumin
indicated absence of significant changes in the vasculature
and permeability after VEGF treatment. Altogether, the present
data point to a direct action of VEGF on extraocular
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motoneurons which prevented the lesion-induced decrease
in ChAT. Consequently, VEGF sustained these damaged
motoneurons in a neurotransmissive mode, which is a necessary
prerequisite for neuromuscular function, opening promising
perspectives for the use of VEGF as a therapeutical agent in
motoneuron diseases.
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